Format

Send to

Choose Destination
Eur Cytokine Netw. 2019 Dec 1;30(4):130-134. doi: 10.1684/ecn.2019.0436.

IL-8 as a potential biomarker in Guillain-Barre Syndrome.

Author information

1
Department of Neurosciences, Division of Neurology, Geneva University Hospitals, Geneva, Switzerland.
2
Department of Diagnostic Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland, Department of Medicine, Division of Immunology and Allergy, Geneva University Hospitals, Geneva, Switzerland.
3
Department of Neurosciences, Division of Neurology, Geneva University Hospitals, Geneva, Switzerland, Department of Diagnostic Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Abstract

This pilot study was designed to compare the levels of interleukin-8 (IL-8), a pro-inflammatory chemokine, in the cerebrospinal fluid (CSF) of patients with Guillain-Barre syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), non-inflammatory polyneuropathy (PNP), and other non-inflammatory neurological diseases (functional syndrome or migraine). The results show elevated CSF IL-8 levels in GBS compared to the other groups (pā€‰<ā€‰0.05). IL-8 could be considered a potential biomarker to differentiate GBS from CIDP. This distinction could be relevant in terms of therapeutic decisions and functional prognosis.

KEYWORDS:

cerebrospinal fluid; chemokine; chronic inflammatory demyelinating polyneuropathy; cytokine; inflammation

PMID:
32096474
DOI:
10.1684/ecn.2019.0436

Supplemental Content

Full text links

Icon for John Libbey Eurotext
Loading ...
Support Center